SNSE
Sensei Biotherapeutics, Inc. Common Stock
stock NASDAQ

sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy 'self' tissues from 'non-self'. cancer is a unique challenge to the immune system. it arises from 'self' making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between 'self' and 'non-self' is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit